Burgaz A., Orsini N., Larsson S.C., Wolk A. (2011) Blood 25-hydroxyvitamin D concentration and hypertension: a metaanalysis. J Hypertens 29: 636–645.

Burr D.B., Diab T., Koivunemi A., Koivunemi M., Allen M.R. Effects of 1 to 3 years’ treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk. J Orthop Res. 2009. Oct. 27(10): 1288–92.

Chesnut C.H., Skag A., Christiansen C., Recker R., Stakkestad J.A., Hoiseth A., Felsenberg D., Huss H., Gibride J., Schimmer R.C., Delmas P.D. Effects of oral ibandronate administered daily or intermittenly on fracture risk in postmenopausal osteoporosis //J. Bone and Mineral Research. 2004. Vol. 19. Р. 1241–1249.

Cramer J., Amonkar M.M., Hebborn A. et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis // Curr. Med. Res. Opin. 2005. V. 21. P. 1453–1460.

Cross H.S., Kallay, E. Regulation of the colonic vitamin D system for prevention of tumor progression: an update. Future Oncol. 2009, 5, 493–507.

Cryer B., Miller P., Petruschke R.A., Chen E., Geba G.P., Papp A.E. Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use. Aliment Pharmacol Ther. 2005. Mar 1. 21(5): 599–607.

Dobnig H., Pilz S., Scharnagl H., Renner W., Seelhorst U., Wellnitz B., Kinkeldei J., Boehm B.O., Weihrauch G., Maerz W. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 2008, 168, 1340–1349.

Emkey R., Koltun W., Beusterien K. et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO) // Curr Med Res Opin. 2005. 21(12): 1895–1903.

Felsenberg D., Hoffmeister B., Amling M., Seibel M.J., Fratzl P. Kiefemekrosen nach hoch dosierter bisphosphonattherapie // Dtsch Arzebl. 2006. Vol. 103. Р. 3078–3081.

Foley R.N., Collins A.J., Ishani A., Kalra P.A. (2008) Calciumphosphate levels and cardiovascular disease in communitydwelling adults: the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 156: 556–563;!!!Vestergaard P., Mollerup C.L., Frokjaer V.G., Christiansen P., Blichert-Toft M., Mosekilde L. (2003) Cardiovascular events before and after surgery for primary hyperparathyroidism. World J Surg 27: 216–222.

Giovannucci E., Liu Y., Hollis B.W., Rimm E.B. (2008) 25-Hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 168:1174–1180.

Graham D. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci. 2002. 47(8): 1665–78.

Halkin H., Dushenat M., Silverman B. еt al. Brand versus generic alendronate: gastrointestinal effects measured by resource utilization. Ann Pharmacother. 2007. 41(1): 29–34.

http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021817s003lbl.pdf

http://www.biomedcentral.com/content/pdf/1471-2474-10-113.pdf

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150837.htm

http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm079352.htm

Ing-Lorenzini K., Desmeules J., Plachta O., Suva D., Dayer P., Peter R. Low-energy femoral fractures associated with the longterm use of bisphosphonates: a case series from a Swiss university hospital // Drug Saf. 2009. Vol. 32. Р. 775–785.

Jackson R.D., LaCroix A.Z., Gass M. et al. (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683; Hsia J., Heiss G., Ren H. et al. (2007) Calcium/vitamin D supplementation and cardiovascular events. Circulation 115: 846–854.

Janja Zupan, Radko Komadina, Janja Marc. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues // J Biomed Sci. 2012; 19(1): 28. Published online 2012 March 1.

Jarvinen T.L.N., Sievanen H., Khan K.M., Heinonen А., Kannus Р. Shifting the focus in fracture prevention from osteoporosis to falls. BMJ. 2008. 336: 124–126.

Kendler D., Kung A.W., Fuleihan Gel H. et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate // Maturitas. 2004. V. 48. P. 243–251.

Lampropoulos, C. E. et al. Osteoporosis – a risk factor for cardiovascular disease? // Nat. Rev. Rheumatol. advance online publication 14 August 2012.